3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Philadelphia Chromosome
2
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia
1
Interventions
ruxolitinib
6
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Cytarabine
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Methotrexate
4
Daunorubicin
4
Thioguanine
3
Tacrolimus
3
Etoposide
3
Early Intervention, Educational
3
Cyclophosphamide
3
ponatinib
2
parsaclisib
2
nilotinib
2
merphos
2
luspatercept
2
fludarabine
2
fedratinib
2
anagrelide
2
Tretinoin
2
Therapeutics
2
Psychiatric Rehabilitation
2
Mitoxantrone
2
Filgrastim
2
Cyclosporins
2
Cyclosporine
2
Busulfan
2
Asparaginase
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Myeloproliferative Disorders
×
asciminib
×
Clear all
NCT05456191
2026-05-27
ASC4START
Novartis
Phase 3
Active not recruiting
568 enrolled
11 charts